Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Stock Short Interest Report for October

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totaling 300,482 shares, an increase of 109.3% from the September 30th total of 143,564 shares. Based on an average daily volume of 92,193 shares, the short-interest ratio is presently 3.3 days. Currently, 0.2% of the shares of the stock are sold short.

Xtant Medical Stock Performance

Shares of XTNT stock traded down $0.01 during trading on Friday, hitting $0.28. The company’s stock had a trading volume of 44,518 shares, compared to its average volume of 100,139. The business has a fifty day moving average of $0.33 and a 200-day moving average of $0.46. The company has a current ratio of 2.16, a quick ratio of 1.05 and a debt-to-equity ratio of 0.18. Xtant Medical has a 52 week low of $0.27 and a 52 week high of $0.95. The company has a market cap of $39.31 million, a PE ratio of -3.50 and a beta of -0.20.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its earnings results on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.05). Xtant Medical had a negative net margin of 10.17% and a negative return on equity of 23.45%. The company had revenue of $23.03 million for the quarter, compared to analysts’ expectations of $24.88 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Xtant Medical stock. AWM Investment Company Inc. acquired a new position in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 5,976,910 shares of the medical device company’s stock, valued at approximately $2,516,000. AWM Investment Company Inc. owned approximately 4.26% of Xtant Medical at the end of the most recent reporting period. Institutional investors own 69.33% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Loop Capital set a $1.00 price target on shares of Xtant Medical in a report on Wednesday, September 2nd. Two research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Xtant Medical has a consensus rating of “Buy” and a consensus target price of $1.00.

About Xtant Medical

Xtant Medical Holdings, Inc is a medical technology company focused on developing, manufacturing and distributing orthobiologic and spinal implant products. Its offerings are designed to support bone growth, spinal fusion and the repair or reconstruction of musculoskeletal tissue.

The company’s product portfolio includes biologic materials such as allograft and other regenerative tissue products, along with spinal implants, interbody devices, fixation systems and related surgical instruments.